Sign in

You're signed outSign in or to get full access.

Muhammad Azrul bin Abdul Hamid

Director at BioNexus Gene Lab
Board

About Muhammad Azrul bin Abdul Hamid

Independent director since December 11, 2023; age 49 as of September 16, 2024, with 20+ years of legal experience in Malaysian High Court and Court of Appeal matters across IP, contracts, debt collection, and torts, and advisory work for technology IP protection and enforcement . He is a member of the Malaysian Eurocham IP Committee, Kuala Lumpur Bar Committee IT Committee, and Bar Council Cyberlaw Committee, and a contributor/speaker for the South East Asia EU‑SME IPR Helpdesk . He is determined independent under Nasdaq rules and listed as an independent director in FY2024 filings .

Past Roles

OrganizationRoleTenureCommittees/Impact
Malaysian High Court / Court of Appeal (Malaysia)Lawyer litigating IP, contracts, debt collection, tort claims20+ years (not individually dated) Extensive litigation and advisory practice
Technology industry clients (advisory)Advisor on IP protection and enforcementNot disclosed Public policy and government engagement for startups/SMEs/MNCs

External Roles

OrganizationRoleTenureNotes
Malaysian Eurocham IP CommitteeMemberNot disclosed IP policy engagement
Kuala Lumpur Bar Committee IT CommitteeMemberNot disclosed Legal/IT interface
Bar Council Cyberlaw CommitteeMemberNot disclosed Cyberlaw governance
South East Asia EU‑SME IPR HelpdeskContributor and regular speakerNot disclosed SME IP education

Board Governance

  • Board committees: Audit (member), Compensation (Chair), Nominating & Corporate Governance (Chair) .
  • Independence: Determined “independent” under Nasdaq; Board has majority independent directors ; FY2024 filing lists him among independent directors .
  • Lead Independent Director: None appointed given board size; independents meet with auditors without management .
  • Tenure and elections: Appointed Dec 11, 2023 by written consent; committee appointments confirmed Jan 22, 2024; re‑elected Oct 4, 2024 .
  • Attendance context: FY2023 had 4 board meetings; committees each met twice; company expects incumbent directors to attend ≥75% (FY2023 data precedes his tenure) .
CommitteeRoleIndependenceCharter Reviewed AnnuallyNotes
AuditMemberYes Yes Oversight of accounting, reporting, PCAOB communications
CompensationChairYes Yes Reviews CEO pay, management comp, director comp; no comp consultants used in FY2023
Nominating & Corporate GovernanceChairYes Yes Director nominations, governance policies, independence emphasis

Fixed Compensation

ComponentAmountFrequencyApplicability/Notes
Independent Director Retainer$1,000Per month“Standard independent director compensation” set by Compensation Committee; explicitly applied to new independent director Ms. Jook Yuen Low and described as standard for independent directors
Compensation ConsultantsNone usedFY2023Committee disclosed no consultants in FY2023

Performance Compensation

ItemStatus/DetailsVote/OutcomeNotes
2024 Stock Incentive Plan (covering officers, directors, employees, consultants)Board adopted subject to shareholder approval; designed to grant equity awards if approved Not approved at Oct 4, 2024 annual meeting: For 4,094,117; Against 6,382,176; Abstain 495; Uncast 7,490,875 Without approval, no director equity grants under this plan

As of the 2024 annual meeting, no director performance‑linked equity award structure was implemented; no director‑specific performance metrics disclosed .

Other Directorships & Interlocks

CategoryCompanyRoleCommitteesNotes
Public company boards (current)None disclosed in DEF 14A biography for Mr. Azrul
Public company boards (prior)None disclosed
Private/Non‑profit/AffiliationsSee External Roles aboveMember/ContributorAdvisory and committee roles in legal/IP bodies

Expertise & Qualifications

  • 20+ years legal practice spanning IP, contractual, debt collection, tort claims; technology IP advisory; public policy and government engagement experience .
  • Active roles in legal/IP professional committees (Eurocham IP, Bar IT, Bar Cyberlaw); frequent contributor/speaker for EU‑SME IPR Helpdesk .
  • Board qualifications: Company cites “extensive experience with legal matters” as rationale for Board service .

Equity Ownership

MeasureAs of Sep 3, 2024As of Jan 31, 2025Notes
Beneficial ownership (shares)Dash (“—”) reported in both proxy tables; no specific share count disclosed
% of shares outstandingOutstanding shares: 17,967,663 at both dates
Vested/Unvested breakdownNot disclosed Not disclosed
Shares pledgedNot disclosed Not disclosed

Director Election Support Signal (Oct 4, 2024)

DirectorFORAGAINSTABSTAINUNCAST
Muhammad Azrul bin Abdul Hamid4,119,842 6,355,920 1,217 7,490,456

Plurality standard led to re‑election; however, FOR votes for Mr. Azrul were materially lower than AGAINST, indicating weak shareholder support relative to certain peers (e.g., Koon Wai Wong FOR 10,458,424; AGAINST 17,107) .

Related‑Party Transactions & Conflicts

  • FY2024 10‑K discloses related‑party transactions at subsidiary Chemrex (sales/purchases/rent with Honkuk Material Sdn. Bhd.; RP Products Sdn. Bhd.) with retrospective Audit Committee review and enhanced oversight; no independent director had a material interest in disclosed transactions .
  • Audit Committee investigation identified lapses: unapproved property sale (subsequently canceled), unapproved director remuneration increases and payments, procurement issues; governance remediation implemented (enhanced controls, internal audit) .
  • Internal control deficiency disclosed: disclosure controls not effective due to Chemrex oversight gaps after resignations; remediation underway .

Governance Assessment

  • Strengths:

    • Independent director with legal and IP governance expertise; chairs both Compensation and Nominating & Corporate Governance committees, indicating board trust in his governance leadership .
    • Board majority independent; committees operate under annually reviewed charters; ability for independents to meet auditors without management .
    • Active Audit Committee role amid remediation of subsidiary governance issues, adopting a Related Party Transactions Policy with pre‑approval and monitoring .
  • Concerns/RED FLAGS:

    • Weak shareholder support in Oct 2024 re‑election (AGAINST exceeded FOR), signaling investor skepticism about board effectiveness and/or recent governance events .
    • Disclosure controls deemed ineffective at year‑end FY2024 due to subsidiary governance lapses—material governance risk until remediation is evidenced .
    • Stock Incentive Plan not approved by shareholders, potentially reflecting concerns about dilution or compensation governance; limits equity‑based alignment tools for directors in the near term .
    • Nasdaq minimum bid price exception and reverse split executed post‑annual meeting failure, adding to investor confidence risk around strategic/board actions .
  • Alignment:

    • No disclosed share ownership for Mr. Azrul as of Sep 3, 2024 and Jan 31, 2025; absence of equity holdings may limit direct economic alignment with shareholders pending any future policy revisions or equity grants (none possible without plan approval in 2024) .
  • Compensation governance:

    • Independent director cash retainer set at $1,000/month; no director equity awarded under the unapproved 2024 plan; no compensation consultants used in FY2023 .

Overall, Mr. Azrul’s committee leadership and legal/IP background are positives for governance, but shareholder vote signals and internal control disclosures represent meaningful risks to investor confidence until remediation outcomes and future vote support improve .